Documentos relacionados

1. Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.
2. Comparison of rituximab and intravenous immunoglobulin in the treatment of autoimmune bullous diseases: Real-life data from a single centre.
3. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
4. The clinical features of combined central and peripheral demyelination and antibodies against the node of Ranvier.
5. Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.
6. Real-world results with IgPro20 for hypo- or agammaglobulinemia in Japan.
7. A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies.
8. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy.
9. Trial of Intravenous Immune Globulin in Dermatomyositis.
10. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.